(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 92.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.3%.
Liquidia's revenue in 2026 is $158,320,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $52,852,796,803, with the lowest LQDA revenue forecast at $36,434,435,247, and the highest LQDA revenue forecast at $65,958,055,828. On average, 10 Wall Street analysts forecast LQDA's revenue for 2027 to be $83,045,205,900, with the lowest LQDA revenue forecast at $44,761,248,788, and the highest LQDA revenue forecast at $121,333,568,733.
In 2028, LQDA is forecast to generate $96,925,871,900 in revenue, with the lowest revenue forecast at $60,162,769,833 and the highest revenue forecast at $120,188,081,156.